GLP-1 Compounded Drug Purity Research Study Findings

As compounded and follow-on versions of popular GLP-1 receptor agonists (GLP-1 RAs) flood the market, a newly published study is drawing attention to critical questions about their purity, stability, and potential to trigger unwanted immune responses. Published in Pharmaceutical Research (July 2026), the peer-reviewed investigation by Kopp, Lamberth, Schelde, and colleagues provides some of the most detailed laboratory-level comparisons to date between originator GLP-1 RA products and their compounded or follow-on counterparts — and the findings are worth understanding carefully before making any clinical or personal decisions.

What This Study Found

Researchers analyzed multiple samples of compounded and follow-on products for two widely used GLP-1 receptor agonists: semaglutide and liraglutide. Using a battery of sophisticated laboratory methods — including MAPPs (MHC-II-associated peptide proteomics assay), liquid chromatography-mass spectrometry (LC-MS), photostability testing, and fibrillation assays — the team systematically compared these alternative products against their respective originator formulations.

The study found that both the follow-on drug substances and the compounded products displayed distinct impurity profiles when compared to the originators. Specifically, researchers identified amino acid deletions and additions, as well as unidentified impurities not present in the reference products. These structural variations are not trivial; even small changes in a peptide's amino acid sequence can alter how the immune system recognizes and responds to it.

When compounded semaglutide products were exposed to light — simulating real-world storage and handling conditions — researchers observed significant disparities in strength, total impurity sum, and high-molecular-weight protein levels compared to the originator product. This suggests that compounded formulations may be more vulnerable to degradation under conditions that patients might realistically encounter during storage or use.

The liraglutide follow-on products showed reduced physical stability relative to the originator, which could have implications for product integrity over time. The study also points to variability in the sourcing of the active pharmaceutical ingredient (API), manufacturing processes, and storage conditions as likely contributors to these differing impurity profiles.

Perhaps most notably, when monocyte-derived dendritic cells from healthy human donors were stimulated with the identified peptide impurities, the cells presented various potentially immunogenic peptides — with a distinct number and distribution compared to what was seen with the originator products. This is important because dendritic cells play a central role in activating the adaptive immune response. The study suggests these impurities pose an increased potential for immunogenicity, meaning they could theoretically prompt the immune system to generate antibodies against the drug — or in rare cases, against the patient's own tissues.

It is important to note that these findings are based on in vitro (laboratory) testing. While these methods are scientifically validated tools for predicting immunogenicity risk, the authors themselves underscore that clinical immunogenicity studies in human patients are needed to confirm the real-world implications of these laboratory observations.

Clinical Significance

Immunogenicity — the tendency of a drug to provoke an immune response — is a well-recognized concern in the development of biologic and peptide-based therapeutics. When a patient's immune system generates antibodies against a therapeutic peptide, several consequences are possible: reduced drug efficacy as neutralizing antibodies block the drug's mechanism of action, hypersensitivity or allergic reactions, and in rare but serious cases, cross-reactivity with endogenous proteins.

For GLP-1 receptor agonists specifically, which are prescribed for conditions including type 2 diabetes and obesity management, a loss of therapeutic efficacy due to immune-mediated drug neutralization could have meaningful health consequences. Patients may not achieve expected outcomes in glycemic control or weight management, potentially without a clear clinical explanation.

The study's authors argue that the distinct impurity profiles of follow-on and compounded products could lead to undesirable immune responses in patients — a concern that is amplified by the sheer volume of people now using these medications. They conclude that in vitro immunogenicity assays and, critically, formal clinical immunogenicity studies should be required for GLP-1 RA follow-on and compounded products. Currently, such requirements do not uniformly apply to compounded preparations in the same way they do to FDA-approved biologics or biosimilars.

The findings also raise broader manufacturing and quality control questions. The researchers suggest that variability introduced during API sourcing and the compounding process itself — not just storage conditions — may contribute to the impurity differences observed. This points to systemic, rather than incidental, quality concerns.

Current Access and Compliance Context

The proliferation of compounded GLP-1 RA products has been partly driven by documented shortages of FDA-approved originator products, high out-of-pocket costs for branded medications, and strong consumer demand. Compounding pharmacies are permitted under certain regulatory frameworks to produce medications, including peptide-based drugs, when specific conditions are met. However, compounded products do not undergo the same rigorous pre-market review, standardized manufacturing controls, or post-market surveillance requirements that apply to FDA-approved drugs.

Follow-on products — those that replicate an existing drug but are not formally approved as biosimilars — occupy a similarly complex regulatory space in many jurisdictions. Unlike biosimilars, which must demonstrate analytical, functional, and clinical comparability to a reference product through a structured FDA approval pathway, follow-on products may not be subject to the same level of scrutiny.

This study adds a layer of scientific data to an already complex regulatory and clinical conversation. Researchers suggest that the assumptions of equivalence between compounded or follow-on products and their originators may not be supported at the molecular level, particularly with respect to impurity profiles and immunogenic potential.

What Patients Should Know

If you are currently using or considering a GLP-1 receptor agonist — whether an FDA-approved originator product, a biosimilar, a follow-on, or a compounded version — this research highlights several important points to discuss with your prescribing physician or pharmacist:

• Source matters: The study suggests that where a product's active ingredient comes from and how it is manufactured and stored can affect its impurity profile, which in turn may affect its safety and immunogenic potential.
• Stability under real-world conditions: Compounded semaglutide showed greater degradation when exposed to light compared to the originator, suggesting proper storage handling may be even more critical for these formulations.
• Immune responses are not always obvious: An immune response to a therapeutic peptide does not always cause dramatic symptoms. Reduced efficacy over time — unexplained by diet, lifestyle, or adherence — could in some cases reflect immune-mediated drug neutralization.
• Clinical data in humans is still needed: These are in vitro findings. Researchers acknowledge that formal clinical studies are necessary to determine the actual rate and severity of immunogenicity events in patients using these alternative products.
• Ask questions: Patients have the right to understand the regulatory status and manufacturing standards behind any medication they are prescribed. Working with a knowledgeable, qualified healthcare provider is essential.

Conclusion

The research by Kopp, Lamberth, Schelde, and colleagues represents a significant contribution to the scientific conversation surrounding the safety and quality of compounded and follow-on GLP-1 receptor agonists. While these are in vitro findings that require follow-up with clinical human studies, the data suggest that meaningful molecular differences exist between originator products and their alternatives — differences with potential immunological consequences.

As the use of GLP-1 receptor agonists continues to expand, patients deserve access to accurate, evidence-based information and the guidance of qualified medical professionals. If you have questions about GLP-1 receptor agonists or other peptide-based therapies, we encourage you to consult with a knowledgeable physician who can help you evaluate your options based on your individual health profile.

Find a qualified provider near you at peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content summarizes peer-reviewed research findings and should not be used as a substitute for professional medical consultation. Always speak with a qualified healthcare provider before making any decisions regarding your medications or treatment plan.

---

Citation (AMA format): Kopp KL, Lamberth K, Schelde O, et al. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. Pharm Res. 2026. doi:10.1007/s11095-026-04146-9. PMID: 42533250.